Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

Clinical trial NCT02542696 · COMPLETED

Trial details

NCT number: NCT02542696
Sponsor: Sumitomo Pharma America, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Parkinson Disease

Start date: 2015-08-31
Primary completion: 2022-11-08
Enrollment: 496

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.